Last reviewed · How we verify
Metformin / Placebo treatment for 4 months
Metformin / Placebo treatment for 4 months is a Biguanide Small molecule drug developed by Norwegian University of Science and Technology. It is currently FDA-approved for Type 2 diabetes mellitus, Prediabetes (investigational use in this trial context).
Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in patients with type 2 diabetes.
Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in patients with type 2 diabetes. Used for Type 2 diabetes mellitus, Prediabetes (in research/prevention contexts).
At a glance
| Generic name | Metformin / Placebo treatment for 4 months |
|---|---|
| Sponsor | Norwegian University of Science and Technology |
| Drug class | Biguanide |
| Target | AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and enhancing peripheral glucose uptake and utilization. It may also improve insulin sensitivity and reduce intestinal glucose absorption. The drug does not stimulate insulin secretion, making it useful in various metabolic conditions.
Approved indications
- Type 2 diabetes mellitus
- Prediabetes (investigational use in this trial context)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Metallic taste
- Vitamin B12 deficiency
- Lactic acidosis (rare)
Key clinical trials
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Glycemic Regulation as Endometriosis Adjunct Treatment (PHASE2)
- An Endometrial Cancer Chemoprevention Study of Metformin (PHASE3)
- METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia (PHASE2)
- Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease (PHASE2)
- The RCT of Acupuncture on PCOS Combined With IR (PHASE3)
- The Health Influences of Puberty (HIP) Study (PHASE4)
- Vitamin B12 Supplementation in Diabetic Neuropathy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin / Placebo treatment for 4 months CI brief — competitive landscape report
- Metformin / Placebo treatment for 4 months updates RSS · CI watch RSS
- Norwegian University of Science and Technology portfolio CI
Frequently asked questions about Metformin / Placebo treatment for 4 months
What is Metformin / Placebo treatment for 4 months?
How does Metformin / Placebo treatment for 4 months work?
What is Metformin / Placebo treatment for 4 months used for?
Who makes Metformin / Placebo treatment for 4 months?
What drug class is Metformin / Placebo treatment for 4 months in?
What development phase is Metformin / Placebo treatment for 4 months in?
What are the side effects of Metformin / Placebo treatment for 4 months?
What does Metformin / Placebo treatment for 4 months target?
Related
- Drug class: All Biguanide drugs
- Target: All drugs targeting AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
- Manufacturer: Norwegian University of Science and Technology — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Indication: Drugs for Prediabetes (investigational use in this trial context)
- Compare: Metformin / Placebo treatment for 4 months vs similar drugs
- Pricing: Metformin / Placebo treatment for 4 months cost, discount & access